Literature DB >> 28062627

Association of Repeatedly Measured High-Sensitivity-Assayed Troponin I with Cardiovascular Disease Events in a General Population from the MORGAM/BiomarCaRE Study.

Maria F Hughes1,2,3,4, Francisco Ojeda2, Olli Saarela5,6, Torben Jørgensen7,8,9, Tanja Zeller2,3, Tarja Palosaari6, Mark G O'Doherty10, Anders Borglykke7, Kari Kuulasmaa6, Stefan Blankenberg2,3, Frank Kee10.   

Abstract

BACKGROUND: High-sensitivity troponin I (hs-cTnI) concentrations reflect myocardial stress. The role of hs-cTnI in predicting long-term changes in the risk of cardiovascular disease (CVD) in general populations is not clearly defined.
METHODS: We investigated whether the change in 3 repeated measures of hs-cTnI collected 5 years apart in a prospective Danish study (3875 participants, initially aged 30-60 years, 51% female, disease free at baseline) improves 10-year prediction of incident CVD compared to using a single most recent hs-cTnI measurement. The change process was modelled using a joint (longitudinal and survival) model and compared to a Cox model using a single hs-cTnI measure adjusted for classic CVD risk factors, and evaluated using discrimination statistics.
RESULTS: Median hs-cTnI concentrations changed from 2.6 ng/L to 3.4 ng/L over 10 years. The change in hs-cTnI predicts 10-year risk of CVD (581 events); the joint model gave a hazard ratio of 1.31 per interquartile difference in hs-cTnI (95% CI 1.15-1.48) after adjustment for CVD risk factors. However, the joint model performed only marginally better (c-index improvement 0.0041, P = 0.03) than using a single hs-cTnI measure (c-index improvement 0.0052, P = 0.04) for prediction of CVD, compared to a model incorporating CVD risk factors without hs-cTnI (c-index 0.744).
CONCLUSIONS: The change in hs-cTnI in 5-year intervals better predicts risk of CVD in the general population, but the most recent measure of hs-cTnI, (at 10 years) is as effective in predicting CVD risk. This simplifies the use of hs-cTnI as a prognostic marker for primary prevention of CVD in the general population.
© 2016 American Association for Clinical Chemistry.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 28062627     DOI: 10.1373/clinchem.2016.261172

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  9 in total

1.  Is twice better than once?-challenges of troponin measurements for risk prediction in the general population.

Authors:  Henning Jansen; Dietrich Rothenbacher; Wolfgang Koenig
Journal:  Ann Transl Med       Date:  2019-09

Review 2.  Revisiting the Biological Variability of Cardiac Troponin: Implications for Clinical Practice.

Authors:  Nick S R Lan; Damon A Bell
Journal:  Clin Biochem Rev       Date:  2019-11

3.  Repeat Measurements of High Sensitivity Troponins for the Prediction of Recurrent Cardiovascular Events in Patients With Established Coronary Heart Disease: An Analysis From the KAROLA Study.

Authors:  Henning Jansen; Andrea Jaensch; Ben Schöttker; Dhayana Dallmeier; Roman Schmucker; Hermann Brenner; Wolfgang Koenig; Dietrich Rothenbacher
Journal:  J Am Heart Assoc       Date:  2019-06-13       Impact factor: 5.501

4.  Biomarker profiling for risk of future heart failure (HFpEF) development.

Authors:  Chris J Watson; Joe Gallagher; Mark Wilkinson; Adam Russell-Hallinan; Isaac Tea; Stephanie James; James O'Reilly; Eoin O'Connell; Shuaiwei Zhou; Mark Ledwidge; Ken McDonald
Journal:  J Transl Med       Date:  2021-02-09       Impact factor: 5.531

5.  Relationship between cardiac biomarker concentrations and long-term mortality in subjects with osteoarthritis.

Authors:  Martin Rehm; Gisela Büchele; Raphael Simon Peter; Rolf Erwin Brenner; Klaus-Peter Günther; Hermann Brenner; Wolfgang Koenig; Dietrich Rothenbacher
Journal:  PLoS One       Date:  2020-12-02       Impact factor: 3.240

6.  Modelling of longitudinal data to predict cardiovascular disease risk: a methodological review.

Authors:  David Stevens; Deirdre A Lane; Stephanie L Harrison; Gregory Y H Lip; Ruwanthi Kolamunnage-Dona
Journal:  BMC Med Res Methodol       Date:  2021-12-18       Impact factor: 4.615

Review 7.  Biomarkers of HFpEF: Natriuretic Peptides, High-Sensitivity Troponins and Beyond.

Authors:  Paolo Morfino; Alberto Aimo; Vincenzo Castiglione; Giuseppe Vergaro; Michele Emdin; Aldo Clerico
Journal:  J Cardiovasc Dev Dis       Date:  2022-08-10

8.  Predictive value of long-term changes of growth differentiation factor-15 over a 27-year-period for heart failure and death due to coronary heart disease.

Authors:  Nina Fluschnik; Francisco Ojeda; Tanja Zeller; Torben Jørgensen; Kari Kuulasmaa; Peter Moritz Becher; Christoph Sinning; Stefan Blankenberg; Dirk Westermann
Journal:  PLoS One       Date:  2018-05-17       Impact factor: 3.240

9.  Cardiac troponin I in SARS-CoV-2-patients: The additional prognostic value of serial monitoring.

Authors:  Martina Zaninotto; Monica Maria Mion; Andrea Padoan; Luciano Babuin; Mario Plebani
Journal:  Clin Chim Acta       Date:  2020-10-01       Impact factor: 3.786

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.